Skip to Content
 

VICC toll-free number 1-877-936-8422

Eugenia M. Yazlovitskaya, Ph.D.

Research Associate Professor of Medicine (Nephrology)

Contact Information:

Vanderbilt University Medical Center
1301 22nd Avenue South, B-902 TVC
Nashville, TN 37232-5671
615-322-1038
Fax: 615-343-3061

Publications
  • Linkous AG, Yazlovitskaya EM. Novel radiosensitizing anticancer therapeutics. Anticancer Res. 2012 Jul; 32(7): 2487-99. PMID: 22753705, PII: 32/7/2487, ISSN: 1791-7530.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22753705.
  • Schulte RR, Linkous AG, Hallahan DE, Yazlovitskaya EM. Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer. Cancer Lett. 2011 May 5/28/2011; 304(2): 137-43. PMID: 21397389, PMCID: PMC3075208, PII: S0304-3835(11)00088-7, DOI: 10.1016/j.canlet.2011.02.015, ISSN: 1872-7980.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21397389.
  • Schleicher SM, Thotala DK, Linkous AG, Hu R, Leahy KM, Yazlovitskaya EM, Hallahan DE. Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. PLoS ONE [print-electronic]. 2011; 6(7): e22182. PMID: 21799791, PMCID: PMC3140496, PII: 10-PONE-RA-19483, DOI: 10.1371/journal.pone.0022182, ISSN: 1932-6203.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21799791.
  • Thotala DK, Geng L, Dickey AK, Hallahan DE, Yazlovitskaya EM. A new class of molecular targeted radioprotectors: GSK-3beta inhibitors. Int. J. Radiat. Oncol. Biol. Phys. 2010 Feb 2/1/2010; 76(2): 557-65. PMID: 20117291, PMCID: PMC2873869, PII: S0360-3016(09)03220-9, DOI: 10.1016/j.ijrobp.2009.09.024, ISSN: 1879-355X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20117291.
  • Kobayashi H, Yazlovitskaya EM, Lin PC. Interleukin-32 positively regulates radiation-induced vascular inflammation. Int. J. Radiat. Oncol. Biol. Phys. 2009 Aug 8/1/2009; 74(5): 1573-9. PMID: 19616744, PMCID: PMC2713876, PII: S0360-3016(09)00580-X, DOI: 10.1016/j.ijrobp.2009.04.017, ISSN: 1879-355X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19616744.
  • Linkous A, Geng L, Lyshchik A, Hallahan DE, Yazlovitskaya EM. Cytosolic phospholipase A2: targeting cancer through the tumor vasculature. Clin. Cancer Res [print-electronic]. 2009 Mar 3/1/2009; 15(5): 1635-44. PMID: 19240173, PMCID: PMC2874582, PII: 1078-0432.CCR-08-1905, DOI: 10.1158/1078-0432.CCR-08-1905, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19240173.
  • Yazlovitskaya EM, Linkous AG, Thotala DK, Cuneo KC, Hallahan DE. Cytosolic phospholipase A2 regulates viability of irradiated vascular endothelium. Cell Death Differ [print-electronic]. 2008 Oct; 15(10): 1641-53. PMID: 18566601, PII: cdd200893, DOI: 10.1038/cdd.2008.93, ISSN: 1350-9047.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18566601.
  • Thotala DK, Hallahan DE, Yazlovitskaya EM. Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation. Cancer Res. 2008 Jul 7/15/2008; 68(14): 5859-68. PMID: 18632640, PII: 68/14/5859, DOI: 10.1158/0008-5472.CAN-07-6327, ISSN: 1538-7445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18632640.
  • Yazlovitskaya EM, Edwards E, Thotala D, Fu A, Osusky KL, Whetsell WO, Boone B, Shinohara ET, Hallahan DE. Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation. Cancer Res. 2006 Dec 12/1/2006; 66(23): 11179-86. PMID: 17145862, PII: 66/23/11179, DOI: 10.1158/0008-5472.CAN-06-2740, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17145862.
  • Tan J, Geng L, Yazlovitskaya EM, Hallahan DE. Protein kinase B/Akt-dependent phosphorylation of glycogen synthase kinase-3beta in irradiated vascular endothelium. Cancer Res. 2006 Feb 2/15/2006; 66(4): 2320-7. PMID: 16489037, PII: 66/4/2320, DOI: 10.1158/0008-5472.CAN-05-2700, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16489037.